Get the Stockscreener App
11.82
2.80%
-0.34
After Hours:
11.82
Elicio Therapeutics Inc stock is traded at $11.82, with a volume of 119.93K.
It is down -2.80% in the last 24 hours and up +55.32% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$12.16
Open:
$11.94
24h Volume:
119.93K
Relative Volume:
1.00
Market Cap:
$204.00M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.4619
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+0.68%
1M Performance:
+55.32%
6M Performance:
+2.96%
1Y Performance:
+42.93%
1-Day Range:
$11.14
$12.26
1-Week Range:
$11.14
$14.93
52-Week Range:
$4.60
$14.93
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
11.82 | 209.87M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
How (ELTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Elicio Therapeutics (NASDAQ: ELTX) files S-3/A delaying effective date - Stock Titan
Elicio Therapeutics Files $400 Million Mixed Shelf - marketscreener.com
Elicio Therapeutics to issue up to $400 million in securities - marketscreener.com
Elicio Therapeutics To Issue Up To $400 Million In Securities - TradingView
Elicio Therapeutics (NASDAQ: ELTX) files $400M shelf to offer stock, debt - Stock Titan
Analyst Downgrade: Can Elicio Therapeutics Inc lead its sector in growthFed Meeting & High Accuracy Swing Trade Signals - baoquankhu1.vn
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Bitget
Cancer immunotherapy firm Elicio to speak at TD Cowen health conference March 4 - Stock Titan
ELTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Elicio Therapeutics Inc. lead its sector in growth2025 Geopolitical Influence & Verified Technical Trade Signals - mfd.ru
Why Elicio Therapeutics Inc. stock is favored by top institutionsWeekly Gains Summary & Weekly Stock Performance Updates - mfd.ru
Growth Value: Whats next for Elicio Therapeutics Inc stockMarket Risk Report & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Trading Systems Reacting to (ELTX) Volatility - Stock Traders Daily
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - The Manila Times
New Elicio hire gets 30,300 options vesting over 4 years - Stock Titan
What are the future prospects of Elicio Therapeutics Inc.Stop Loss & AI Optimized Trading Strategy Guides - mfd.ru
Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way? - simplywall.st
How Elicio Therapeutics Inc. (ELTX) Affects Rotational Strategy Timing - Stock Traders Daily
Aug Setups: Does Elicio Therapeutics Inc offer margin of safetyNew Guidance & Smart Investment Allocation Tips - baoquankhu1.vn
(ELTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
While insiders own 33% of Elicio Therapeutics, Inc. (NASDAQ:ELTX), individual investors are its largest shareholders with 55% ownership - Yahoo Finance
Loss Report: Is SandRidge Energy Inc a stock for growth or value investorsJuly 2025 Trade Ideas & Safe Swing Trade Setups - baoquankhu1.vn
Retail Trends: Does Elicio Therapeutics Inc offer margin of safetyWall Street Watch & Technical Buy Zone Confirmation - baoquankhu1.vn
Why Elicio Therapeutics Inc. stock is seen as undervaluedEarnings Overview Summary & Risk Controlled Swing Alerts - bollywoodhelpline.com
Responsive Playbooks and the ELTX Inflection - Stock Traders Daily
Aug Volume: Will Elicio Therapeutics Inc benefit from AI trendsJuly 2025 Macro Moves & Weekly Setup with High ROI Potential - baoquankhu1.vn
Profit Review: What are the future prospects of Elicio Therapeutics Inc2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Biotech Elicio offers 22,400 stock options to attract new hires - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Elicio Therapeutics (ELTX) - The Globe and Mail
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why - Eastern Progress
Is Quest Diagnostics (DGX) Stock Outpacing Its Medical Peers This Year? - Eastern Progress
Why Elicio Therapeutics Inc. stock could benefit from AI revolutionJuly 2025 Catalysts & Safe Entry Trade Signal Reports - Улправда
Why CBLL stock attracts strong analyst attention - Улправда
How rising interest rates impact Elicio Therapeutics Inc. stock2025 Technical Overview & Reliable Volume Spike Trade Alerts - ulpravda.ru
KRAS Inhibitors Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Pfizer, Roche, Chugai, Genentech, Revolution Medicines, Eli Lilly, Merck, Taiho, Astex Pharma, Elicio - Barchart.com
How Elicio Therapeutics Inc. stock reacts to Fed rate cutsREITs Market Trends & Free High Margin Investment Plays - Улправда
Understanding the Setup: (ELTX) and Scalable Risk - Stock Traders Daily
What is the fair value of Elicio Therapeutics Inc. stock nowJuly 2025 Drop Watch & Technical Entry and Exit Alerts - Улправда
Dividend Watch: Can Elicio Therapeutics Inc. stock hit record highs again2025 Fundamental Recap & AI Powered Buy and Sell Recommendations - Улправда
Aug Decliners: Why Elicio Therapeutics Inc stock could rally in 2025July 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn
Will Elicio Therapeutics Inc. stock benefit from green energy trendsWeekly Investment Summary & Reliable Entry Point Alerts - Улправда
Is Elicio Therapeutics Inc. stock ready for breakoutJuly 2025 Gainers & Entry Point Confirmation Alerts - bolumsonucanavari.com
FOMO Trade: Can Elicio Therapeutics Inc. stock hit record highs again2025 Geopolitical Influence & Entry and Exit Point Strategies - Улправда
How supply chain issues affect Elicio Therapeutics Inc. stockMarket Movers & Reliable Breakout Forecasts - DonanımHaber
Why Elicio Therapeutics Inc. stock could rally in 2025Earnings Risk Summary & Weekly High Potential Alerts - Улправда
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):